Literature DB >> 18797744

Lung cancer: histology, staging, treatment and survival.

Fabiola Trocoli Novaes1, Daniele Cristina Cataneo, Raul Lopes Ruiz Junior, Júlio Defaveri, Odair Carlito Michelin, Antonio José Maria Cataneo.   

Abstract

OBJECTIVE: To analyze principal histological types of lung cancer, as well as the staging, treatment and survival of lung cancer patients.
METHODS: This was a retrospective study based on the analysis of medical charts of patients treated at the Botucatu School of Medicine Hospital das Clínicas over a six-year period.
RESULTS: From January of 2000 to January of 2006, 240 patients with lung cancer, most (64%) of whom were male, were treated. The most common histological type was squamous cell carcinoma (37.5%), followed by adenocarcinoma (30%), neuroendocrine carcinoma (19.6%) and large cell carcinoma (6.6%). Only 131 patients (54.6%) were treated. Of those, 52 patients (39.7%) received only chemotherapy, 32 (24.4%) were treated with chemotherapy combined with radiotherapy, and 47 (35.9%) were submitted to surgery alone or surgery accompanied by chemotherapy, with or without radiotherapy. Only 27 patients (20.6%) were submitted to surgery alone. Concerning staging, 34.4% presented stage IV at the time of diagnosis, 20.6% presented stage IIIB, 16.8% presented stage IIIA, and the remaining 28.2% were classified as stage I or II. Five-year survival was 65% for those in stage I and 25% for those in the remaining stages.
CONCLUSIONS: Of the various histological types, the most common was squamous cell carcinoma and the least common was large cell carcinoma. Most cases presented advanced stages at the moment of diagnosis, and less than 30% of the cases presented early stages. This accounts for the low survival rate and the small number of patients submitted to surgical treatment alone, the majority being submitted to chemotherapy alone.

Entities:  

Mesh:

Year:  2008        PMID: 18797744     DOI: 10.1590/s1806-37132008000800009

Source DB:  PubMed          Journal:  J Bras Pneumol        ISSN: 1806-3713            Impact factor:   2.624


  20 in total

1.  LIM and SH3 protein 1 promotes tumor proliferation and metastasis in lung carcinoma.

Authors:  Xueqiong Lin; Xianhui Liu; Yusen Fang; Xuefen Weng
Journal:  Oncol Lett       Date:  2016-10-05       Impact factor: 2.967

2.  Overexpression of estrogen receptor beta is a prognostic marker in non-small cell lung cancer: a meta-analysis.

Authors:  Zhuang Luo; Rongrong Wu; Yifeng Jiang; Zhixing Qiu; Wei Chen; Weimin Li
Journal:  Int J Clin Exp Med       Date:  2015-06-15

3.  Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer.

Authors:  Ke Zhao; Jing Cheng; Baojun Chen; Qi Liu; Di Xu; Yongjian Zhang
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

4.  Non-small cell lung cancer in never smokers: a clinical entity to be identified.

Authors:  Ilka Lopes Santoro; Roberta Pulcheri Ramos; Juliana Franceschini; Sergio Jamnik; Ana Luisa Godoy Fernandes
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

5.  Lung cancer: changes in histology, gender, and age over the last 30 years in Brazil.

Authors:  Maria Teresa Ruiz Tsukazan; Álvaro Vigo; Vinícius Duval da Silva; Carlos Henrique Barrios; Jayme de Oliveira Rios; José Antônio de Figueiredo Pinto
Journal:  J Bras Pneumol       Date:  2017 Sep-Oct       Impact factor: 2.624

6.  MicroRNA-30e-5p promotes cell growth by targeting PTPN13 and indicates poor survival and recurrence in lung adenocarcinoma.

Authors:  Li Zhuang; Tao Shou; Ke Li; Chun-Lin Gao; Lin-Can Duan; Li-Zhou Fang; Qin-Yong Zhang; Zong-Ning Chen; Chao Zhang; Shou-Tao Yang; Gao-Feng Li
Journal:  J Cell Mol Med       Date:  2017-06-27       Impact factor: 5.310

7.  CP-673451, a platelet-derived growth-factor receptor inhibitor, suppresses lung cancer cell proliferation and migration.

Authors:  Yuling Xi; Ming Chen; Xinmin Liu; Zhongmin Lu; Yi Ding; Datong Li
Journal:  Onco Targets Ther       Date:  2014-07-03       Impact factor: 4.147

8.  Comparison of the accuracy of 99mTc-3P4-RGD2 SPECT and CT in diagnosing solitary pulmonary nodules.

Authors:  Haishan Zhang; Shi Gao; Bin Chen; Guanghui Cheng
Journal:  Oncol Lett       Date:  2016-08-17       Impact factor: 2.967

9.  Survival in a cohort of patients with lung cancer: the role of age and gender in prognosis.

Authors:  Juliana Pereira Franceschini; Sérgio Jamnik; Ilka Lopes Santoro
Journal:  J Bras Pneumol       Date:  2017 Nov-Dec       Impact factor: 2.624

10.  Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.

Authors:  Wolfgang M Brueckl; H Jost Achenbach; Joachim H Ficker; Wolfgang Schuette
Journal:  BMC Cancer       Date:  2018-03-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.